• ABVC BioPharma replaced auditor Simon & Edward with Kreit & Chiu as independent accountant for fiscal 2026, effective June 30, 2026.
• Prior audit reports for fiscal 2024 and 2025 carried a going-concern explanatory paragraph.
• No reported disputes with the outgoing auditor on accounting, disclosure, or audit scope through June 30, 2026.
• Only cited reportable issue was previously disclosed material weaknesses in internal control over financial reporting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-074949), on July 02, 2026, and is solely responsible for the information contained therein.